List of Publications


List of Tables

**Table 2.1** Main types of transport systems for targeted delivery of peptides across the BBB  

**Table 4.1** Molecular Formula, Yield, Melting point, R<sub>f</sub>, UV, Log P and Elemental analysis (%) (C, H, N) of DA-1 to DA-6  

**Table 4.2** Molecular Formula, Yield, Melting point, R<sub>f</sub>, UV, Log P and Elemental analysis (%) (C, H, N) of DA-7 to DA-10  

**Table 4.3** Molecular Formula, Yield, Melting point, R<sub>f</sub>, UV, Log P and Elemental analysis (%) (C, H, N) of DA-11 to DA-14  

**Table 4.4** Dopamine, DOPAC and HVA Estimation
List of Figures

**Figure 1.1** Diagrammatic representation of the working of the basal ganglia in a normal and Parkinsonian brain

**Figure 2.1** Major dopaminergic pathways in the human brain

**Figure 2.2** Therapeutic approaches for PD treatment

**Figure 2.3** Signal transduction mechanisms of dopamine

**Figure 2.4** Mechanism of DCC Coupling

**Figure 2.5** Chemical delivery system of dopamine

**Figure 2.6** Blood brain barrier

**Figure 2.7** Interaction of solutes with the blood-brain barrier

**Figure 2.8** The main types of transport systems that can be targeted for BBB delivery

**Figure 3.1** Synthesis of Compounds used reagents and conditions

**Figure 3.2** Synthesis of Compounds used reagents and conditions

**Figure 3.3** Synthesis of Compounds used reagents and conditions

**Figure 4.1** General structure of amino acid conjugates of Dopamine

**Figure 4.2** General structure of conjugates with increasing number of carbon chain between amino-carboxylic group

**Figure 4.3** General structure of dipeptide conjugate of Dopamine

**Figure 4.4** Effects of Std. drug and synthetic compounds DA-1 to DA-6 on the oxotremorine 0.5 mg/kg i.p. induced tremor in mice

**Figure 4.5** Effects of Std. drug and synthetic compounds DA-1 to DA-6 on the oxotremorine induced tremor in mice at 50 min

**Figure 4.6** Effects of Std. drug and synthetic compounds DA-7 to DA-10 on the oxotremorine 0.5 mg/kg i.p. induced tremor in mice

**Figure 4.7** Effects of Std. drug and synthetic compounds DA-7 to DA-10 on the oxotremorine induced tremor in mice at 50 min

**Figure 4.8** Effects of Std. drug and synthetic compounds DA-11 to DA-14 on the oxotremorine 0.5 mg/kg i.p. induced tremor in mice
Figure 4.9  Effects of Std. drug and synthetic compounds DA-11 to DA-14 on the oxotremorine induced tremor in mice at 50 min

Figure 4.10 Effects of Std. drug and synthetic compounds pretreatment on muscular coordination and locomotor activity

Figure 4.11 Effects of Std. drug and synthetic compounds pretreatment on muscular coordination and locomotor activity

Figure 4.12 Effects of Std. drug and synthetic compounds pretreatment on Malondialdehyde estimation activity

Figure 4.13 Effects of Std. drug and synthetic compounds pretreatment on Malondialdehyde estimation activity

Figure 4.14 Effects of Std. drug and synthetic compounds pretreatment on Glutathione estimation

Figure 4.15 Effects of Std. drug and synthetic compounds pretreatment on Glutathione estimation

Figure 4.16 Effects of Std. drug and synthetic compounds (DA-1 to DA-6) pretreatment on Caspase-3 estimation

Figure 4.17 Effects of Std. drug and synthetic compounds (DA-1 to DA-6) pretreatment on Caspase-3 estimation

Figure 4.18 Effects of Std. drug and synthetic compounds (DA-7 to DA-10) pretreatment on Caspase-8 estimation

Figure 4.19 Effects of Std. drug and synthetic compounds (DA-7 to DA-10) pretreatment on Caspase-8 estimation

Figure 4.20 Effects of Std. drug and synthetic compounds (DA-10 to DA-14) pretreatment on Caspase-9 estimation

Figure 4.21 Effects of Std. drug and synthetic compounds (DA-10 to DA-14) pretreatment on Caspase-9 estimation

Figure 4.22 Photomicrographs of rat striatal section focusing (400x) substantial nigra illustrating tyrosine hydroxylase positive Dopaminic neuron (TH) immunoreactivity in 6-OHDA+L group
Figure 4.23 Photomicrographs of rat striatal section focusing (400x)
substantial nigra illustrating tyrosine hydroxylase positive
Dopaminic neuron (TH) immunoreactivity in Sham group

Figure 4.24 Photomicrographs of rat striatal section focusing (400x)
substantial nigra illustrating tyrosine hydroxylase positive
Dopaminic neuron (TH) immunoreactivity in L+DA-3 group

Figure 4.25 Photomicrographs of rat striatal section focusing (400x)
substantial nigra illustrating tyrosine hydroxylase positive
Dopaminic neuron (TH) immunoreactivity in L+DA-4 group

Figure 4.26 Photomicrographs of rat striatal section focusing (400x)
substantial nigra illustrating tyrosine hydroxylase positive
Dopaminic neuron (TH) immunoreactivity in L+DA-7 group

Figure 4.27 Photomicrographs of rat striatal section focusing (400x)
substantial nigra illustrating tyrosine hydroxylase positive
Dopaminic neuron (TH) immunoreactivity in L+DA-9 group

Figure 4.28 Photomicrographs of rat striatal section focusing (400x)
substantial nigra illustrating tyrosine hydroxylase positive
Dopaminic neuron (TH) immunoreactivity in L+DA-11 group